Tokio Marine Asset Management Co. Ltd. Has $678,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tokio Marine Asset Management Co. Ltd. lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,575 shares of the medical equipment provider’s stock after selling 1,117 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Zimmer Biomet were worth $678,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Naples Money Management LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth approximately $35,000. Activest Wealth Management lifted its stake in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares during the last quarter. Peoples Bank KS bought a new stake in Zimmer Biomet during the third quarter worth $48,000. Blue Trust Inc. lifted its stake in Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC lifted its stake in Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.95% of the stock is owned by insiders.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $119.35 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The company has a market cap of $24.52 billion, a PE ratio of 24.41, a P/E/G ratio of 2.20 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The stock has a 50-day moving average of $125.98 and a 200-day moving average of $119.52.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter last year, the firm earned $1.88 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s payout ratio is 19.63%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent analyst reports. Canaccord Genuity Group restated a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a research note on Friday, February 23rd. Barclays increased their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Truist Financial increased their price target on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. Citigroup increased their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.